Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Monday, August 29, 2016

The oncology molecule’s launch offers a new hope for Multiple Sclerosis patients


Click here to receive MS news via e-mail

In May 2016, the Food and Drug Administration (FDA) gave a green signal to Zinbryta—AbbVie Inc.’s (NYSE:ABBV) and Biogen’s mutually-developed molecule molecule—to manage and treat adult patients who suffer from different relapsing ailments of Multiple Sclerosis (MS). In July 2016, the European Commission (EC) approved it for marketing and commercialization in the European countries. The drug is now available in the US therapeutic market.
The regulatory agencies have given the drug an approval based on the scientific data, which showed that it has met primary endpoints in relation to the efficacy and safety profile in two clinical trials. These were the SELECT study and DECIDE study, which aimed to treat MS.
In this regard, AbbVie chief scientific officer and EVP of research and development (R&D) Michael Severino commented: “With the approval of ZINBRYTA in the European Union, we are providing a much-needed treatment option for people living with MS. […] This is an important part of AbbVie’s ongoing commitment to advancing neuroscience research specifically in the area of MS.

MS Views and News
Providing educational information, resources and services for those affected by MS

No comments: